信迪利单抗联合改良DCF方案对晚期胃癌患者肿瘤标志物及miR-133a-3p、miR-4317表达的影响  

Effects of sintilimab combined with modified DCF regimen on tumor markers and expression of miR-133a-3p and miR-4317 in patients with advanced gastric cancer

作　　者：尹余余 王斌 YIN Yuyu;WANG Bin(General Surgery Department,Xingyuan Hospital of Yulin,Yulin 719000,China)

机构地区：[1]榆林市星元医院普外科,陕西榆林719000

出　　处：《临床医学研究与实践》2024年第34期51-54,共4页Clinical Research and Practice

摘　　要：目的探究信迪利单抗联合改良DCF方案对晚期胃癌患者肿瘤标志物及miR-133a-3p、miR-4317表达的影响。方法选取2019年3月至2022年10月我院接收的80例晚期胃癌患者为研究对象,根据治疗方案不同将其分为对照组和观察组,各40例。对照组给予改良DCF方案治疗,观察组给予信迪利单抗联合改良DCF方案治疗。比较两组的肿瘤标志物水平、临床疗效及miR-133a-3p、miR-4317表达量。结果治疗后,观察组的癌胚抗原(CEA)、糖类抗原724(CA724)、糖类抗原199(CA199)水平低于对照组(P<0.05)。观察组的完全缓解(CR)率、客观缓解率(ORR)、疾病控制率(DCR)高于对照组,疾病进展(PD)率低于对照组(P<0.05)。治疗后1周,观察组的miR-133a-3p、miR-4317表达量高于对照组,差异具有统计学意义(P<0.05)。结论信迪利单抗联合改良DCF方案治疗晚期胃癌患者的效果显著,能有效降低肿瘤标志物水平,上调miR-133a-3p、miR-4317表达量。Objective To explore the effects of sintilimab combined with modified DCF regimen on tumor markers and expression of miR-133a-3p and miR-4317 in patients with advanced gastric cancer.Methods A total of 80 patients with advanced gastric cancer received in our hospital from March 2019 to October 2022 were selected as the research objects.According to different treatment schemes,the patients were divided into control group and observation group,with 40 cases in each group.The control group was treated with modified DCF regimen,and the observation group was treated with sintilimab combined with modified DCF regimen.The levels of tumor markers,clinical efficacy and the expression of miR-133a-3p and miR-4317 were compared between the two groups.Results After treatment,the levels of carcino embryonic antigen(CEA),carbohydrate antigen 724(CA724)and carbohydrate antigen 199(CA199)in the observation group were lower than those in the control group(P<0.05).The complete remission(CR)rate,objective response rate(ORR)and disease control rate(DCR)in the observation group were higher than those in the control group,and the progressive disease(PD)rate was lower than that in the control group(P<0.05).At one week after treatment,the expression levels of miR-133a-3p and miR-4317 in the observation group were higher than those in the control group,and the differences were statistically significant(P<0.05).Conclusion The sintilimab combined with modified DCF regimen in the treatment of patients with advanced gastric cancer has a significant effect,it can effectively reduce the levels of tumor markers and up-regulate the expression of miR-133a-3p and miR-4317.

关 键 词：信迪利单抗 改良DCF方案 晚期胃癌 肿瘤标志物 

分 类 号：R735.2[医药卫生—肿瘤]